Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

M. W. C. Verbeek; C. Buracchi; A. Laqua; S. Nierkens; L. Sedek; J. Flores-Montero; M. Hofmans; E. Sobral de Costa; M. Nováková; E. Mejstrikova; S. Barrena; S. Kohlscheen; M. Szczepanowski; J. Kulis; E. Oliveira; R. Jugooa; A. X. de Jong; T. Szczepanski; J. Philippé; J. J. M. van Dongen; A. Orfao; M. Brüggemann; G. Gaipa; V. H. J. van der Velden

doi:10.1111/bjh.17992

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

M. W. C. Verbeek, C. Buracchi, A. Laqua, S. Nierkens, L. Sedek, J. Flores-Montero, M. Hofmans, E. Sobral de Costa, M. Nováková, E. Mejstrikova, S. Barrena, S. Kohlscheen, M. Szczepanowski, J. Kulis, E. Oliveira, R. Jugooa, A. X. de Jong, T. Szczepanski, J. Philippé, J. J. M. van DongenA. Orfao, M. Brüggemann, G. Gaipa, V. H. J. van der Velden^*

^*Corresponding author for this work

Immunology

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

64 Downloads (Pure)

Abstract

The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

Original language	English
Pages (from-to)	76-81
Number of pages	6
Journal	British Journal of Haematology
Volume	197
Issue number	1
DOIs	https://doi.org/10.1111/bjh.17992
Publication status	Published - Apr 2022

Bibliographical note

Funding Information:
JJMvD, AO, JFM, TS and VHJvdV each report being one of the inventors on the EuroFlow‐owned patent PCT/NL2010/050332 (Methods, reagents and kits for flow cytometric immunophenotyping of normal, reactive and malignant leukocytes). The Infinicyt software is based on intellectual property of some EuroFlow laboratories (University of Salamanca in Spain and Federal University of Rio de Janeiro in Brazil) and the scientific input of other EuroFlow members. All above‐mentioned intellectual property and related patents are licensed to Cytognos (Salamanca, Spain) and BD Biosciences (San José, CA, USA), which companies pay royalties to the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow consortium. VHJvdV reports a Laboratory Services Agreement with BD Biosciences; all related fees are for the Erasmus MC. JJMvD and JAOMCV report an Educational Services Agreement from BD Biosciences and a Scientific Advisor Agreement with Cytognos; all related fees and honoraria are for the involved university departments at Leiden University Medical Centre and University of Salamanca. MB received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed, Amgen, BMS and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher Copyright:
© 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

Access to Document

10.1111/bjh.17992Licence: CC BY-NC-ND

Br J Haematol - 2021 - Verbeek - Flow cytometric minimal residual disease assessment in B‐cell precursor acuteFinal published version, 607 KBLicence: CC BY-NC-ND

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85120974952&doi=10.1111%2fbjh.17992&partnerID=40&md5=ddd192e734e951155e66c02fc7508229

Cite this

Verbeek, M. W. C., Buracchi, C., Laqua, A., Nierkens, S., Sedek, L., Flores-Montero, J., Hofmans, M., Sobral de Costa, E., Nováková, M., Mejstrikova, E., Barrena, S., Kohlscheen, S., Szczepanowski, M., Kulis, J., Oliveira, E., Jugooa, R., de Jong, A. X., Szczepanski, T., Philippé, J., ... van der Velden, V. H. J. (2022). Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study. British Journal of Haematology, 197(1), 76-81. https://doi.org/10.1111/bjh.17992

@article{e8b915f095f3451b99d1c1113e9e51af,

title = "Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study",

abstract = "The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92\% of targeted therapy patients who remained CD19-positive, whereas this was 81\% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.",

author = "Verbeek, \{M. W. C.\} and C. Buracchi and A. Laqua and S. Nierkens and L. Sedek and J. Flores-Montero and M. Hofmans and \{Sobral de Costa\}, E. and M. Nov{\'a}kov{\'a} and E. Mejstrikova and S. Barrena and S. Kohlscheen and M. Szczepanowski and J. Kulis and E. Oliveira and R. Jugooa and \{de Jong\}, \{A. X.\} and T. Szczepanski and J. Philipp{\'e} and \{van Dongen\}, \{J. J. M.\} and A. Orfao and M. Br{\"u}ggemann and G. Gaipa and \{van der Velden\}, \{V. H. J.\}",

note = "Funding Information: JJMvD, AO, JFM, TS and VHJvdV each report being one of the inventors on the EuroFlow‐owned patent PCT/NL2010/050332 (Methods, reagents and kits for flow cytometric immunophenotyping of normal, reactive and malignant leukocytes). The Infinicyt software is based on intellectual property of some EuroFlow laboratories (University of Salamanca in Spain and Federal University of Rio de Janeiro in Brazil) and the scientific input of other EuroFlow members. All above‐mentioned intellectual property and related patents are licensed to Cytognos (Salamanca, Spain) and BD Biosciences (San Jos{\'e}, CA, USA), which companies pay royalties to the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow consortium. VHJvdV reports a Laboratory Services Agreement with BD Biosciences; all related fees are for the Erasmus MC. JJMvD and JAOMCV report an Educational Services Agreement from BD Biosciences and a Scientific Advisor Agreement with Cytognos; all related fees and honoraria are for the involved university departments at Leiden University Medical Centre and University of Salamanca. MB received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed, Amgen, BMS and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher Copyright: {\textcopyright} 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley \& Sons Ltd.",

year = "2022",

month = apr,

doi = "10.1111/bjh.17992",

language = "English",

volume = "197",

pages = "76--81",

journal = "British Journal of Haematology",

issn = "0007-1048",

publisher = "John Wiley \& Sons Inc.",

number = "1",

}

Verbeek, MWC, Buracchi, C, Laqua, A, Nierkens, S, Sedek, L, Flores-Montero, J, Hofmans, M, Sobral de Costa, E, Nováková, M, Mejstrikova, E, Barrena, S, Kohlscheen, S, Szczepanowski, M, Kulis, J, Oliveira, E, Jugooa, R, de Jong, AX, Szczepanski, T, Philippé, J, van Dongen, JJM, Orfao, A, Brüggemann, M, Gaipa, G & van der Velden, VHJ 2022, 'Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study', British Journal of Haematology, vol. 197, no. 1, pp. 76-81. https://doi.org/10.1111/bjh.17992

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study. / Verbeek, M. W. C.; Buracchi, C.; Laqua, A. et al.
In: British Journal of Haematology, Vol. 197, No. 1, 04.2022, p. 76-81.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

AU - Verbeek, M. W. C.

AU - Buracchi, C.

AU - Laqua, A.

AU - Nierkens, S.

AU - Sedek, L.

AU - Flores-Montero, J.

AU - Hofmans, M.

AU - Sobral de Costa, E.

AU - Nováková, M.

AU - Mejstrikova, E.

AU - Barrena, S.

AU - Kohlscheen, S.

AU - Szczepanowski, M.

AU - Kulis, J.

AU - Oliveira, E.

AU - Jugooa, R.

AU - de Jong, A. X.

AU - Szczepanski, T.

AU - Philippé, J.

AU - van Dongen, J. J. M.

AU - Orfao, A.

AU - Brüggemann, M.

AU - Gaipa, G.

AU - van der Velden, V. H. J.

N1 - Funding Information: JJMvD, AO, JFM, TS and VHJvdV each report being one of the inventors on the EuroFlow‐owned patent PCT/NL2010/050332 (Methods, reagents and kits for flow cytometric immunophenotyping of normal, reactive and malignant leukocytes). The Infinicyt software is based on intellectual property of some EuroFlow laboratories (University of Salamanca in Spain and Federal University of Rio de Janeiro in Brazil) and the scientific input of other EuroFlow members. All above‐mentioned intellectual property and related patents are licensed to Cytognos (Salamanca, Spain) and BD Biosciences (San José, CA, USA), which companies pay royalties to the EuroFlow Consortium. These royalties are exclusively used for continuation of the EuroFlow collaboration and sustainability of the EuroFlow consortium. VHJvdV reports a Laboratory Services Agreement with BD Biosciences; all related fees are for the Erasmus MC. JJMvD and JAOMCV report an Educational Services Agreement from BD Biosciences and a Scientific Advisor Agreement with Cytognos; all related fees and honoraria are for the involved university departments at Leiden University Medical Centre and University of Salamanca. MB received personal fees from Incyte (advisory board) and Roche Pharma AG, financial support for reference diagnostics from Affimed, Amgen, BMS and Regeneron, grants and personal fees from Amgen (advisory board, speakers bureau, travel support), and personal fees from Janssen (speakers bureau), all outside the submitted work. The other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. Publisher Copyright: © 2021 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.

PY - 2022/4

Y1 - 2022/4

N2 - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

AB - The standardized EuroFlow protocol, including CD19 as primary B-cell marker, enables highly sensitive and reliable minimal residual disease (MRD) assessment in B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) patients treated with chemotherapy. We developed and validated an alternative gating strategy allowing reliable MRD analysis in BCP-ALL patients treated with CD19-targeting therapies. Concordant data were obtained in 92% of targeted therapy patients who remained CD19-positive, whereas this was 81% in patients that became (partially) CD19-negative. Nevertheless, in both groups median MRD values showed excellent correlation with the original MRD data, indicating that, despite higher interlaboratory variation, the overall MRD analysis was correct.

UR - https://www.scopus.com/pages/publications/85120974952

U2 - 10.1111/bjh.17992

DO - 10.1111/bjh.17992

M3 - Article

C2 - 34881427

SN - 0007-1048

VL - 197

SP - 76

EP - 81

JO - British Journal of Haematology

JF - British Journal of Haematology

IS - 1

ER -

Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies — a EuroFlow study

Abstract

Bibliographical note

Access to Document

Other files and links

Fingerprint

Cite this